

R. Lee Buckler, B. Ed, LLB

President, CEO & Director



Lee Buckler has been an executive in the cell therapy sector since 2000 beginning with Malachite Management in the Stem Cell Technologies group of companies. Most recently, he was the Managing Director of Cell Therapy Group, a firm he formed in 2008 where he did business development consulting for companies and organizations in or interested in the cell therapy sector. His work included deal-targeting, transactions, market intelligence, competitive analyses, strategic assessments, and market profile planning for companies ranging from top-tier multinationals to start-ups.

Lee has a Bachelor's Degree in Education and a Law Degree. After law school, Lee did a one-year judicial clerkship with the B.C. Supreme Court and was a practising attorney for three years at Edwards, Kenny & Bray. Lee served six years as the Executive Director of the International Society for Cellular Therapy and just over two years as Director of Business Development for Progenitor Cell Therapy. He is on the editorial advisory boards of the journal *Regenerative Medicine* and the *BioProcess International* magazine, as well as the Co-Chair of the Alliance for Regenerative Medicine's Communications and Education Committee. He co-founded [Cell Therapy News](#), founded [Cell Therapy Blog](#), founded and continues to manage the [LinkedIn Cell Therapy Industry Group](#), co-founded Regenerative Medicine Jobs, and is an active industry commentator in publications and in social media. Lee serves on numerous industry conference advisory boards, is an advisory board member for BioCision, Phacilitate Cell & Gene Therapy and RoosterBio, and is on the Board of Directors for Hemostemix.

Recent publications include a co-authored article in *Cytotherapy*, March 2016 issue titled, "Technological Developments for Small-scale Downstream Processing of Cell Therapies", a book chapter entitled, "State of the Regenerative Medicine Industry" in *The Delivery of Regenerative Medicines and Their Impact on Healthcare* (CRC Press), "Japan's Regulatory Gamble and What it Means for the Industry" in *Cell & Gene Therapy Insights*, Sept. 2015 issue, and "Opportunities in Regenerative Medicine: The Global Industry and Market Trends" in *BioProcess International*, March 2011 Supplement.